Cancer is a condition where there is an uncontrolled growth of cells resulting in high mortality. It is
the second most frequent cause of death worldwide. Bortezomib (BTZ) is a Proteasome Inhibitor (PI) that is
used for the treatment of a variety of cancers. It is the first PI that has received the approval of the US Food and
Drug Administration (FDA) to treat mantle cell lymphoma and multiple myeloma. High incidence of sideeffects,
limited dose, low water solubility, fast clearance, and drug resistance are the significant limitations of
BTZ. Therefore, various drug delivery systems have been tried to overcome these limitations of BTZ in cancer
therapy. Nanotechnology can potentially enhance the aqueous solubility of BTZ, increase its bioavailability, and
control the release of BTZ at the site of administration. The lipid-based nanocarriers, such as liposomes, solid
lipid NPs, and microemulsions, are some of the developments in nanotechnology, which could potentially enhance
the therapeutic benefits of BTZ.
Keywords: Lipid-based nanocarriers, liposomes, solid lipid nanoparticles, microemulsion, Bortezomib, a proteasome inhibitor.
Rights & PermissionsPrintExport